[ad_1]
The European Medicines Agency (EMA), the European Union’s medicines regulatory body, on Friday discovered a possible link between Johnson & Johnson’s COVID-19 vaccine and rare cases of blood clotting in deep veins .
At a meeting of the pharmacovigilance risk assessment committee, the agency said it had found a possible link between venous thromboembolism (VTE) and the J&J vaccine.
“VTE is a disease in which a blood clot forms in a deep vein, usually in a leg, arm or groin, and can travel to the lungs causing a blockage in the blood supply, with consequences. potentially fatal, ”the agency wrote. in his meeting highlights.
It is recommended that the condition be listed as a rare side effect.
The agency also recommends that immune thrombocytopenia (ITP) be listed as a side effect of the J&J vaccine and the AstraZeneca vaccine.
ITP is a bleeding disorder in which “the immune system mistakenly targets blood cells called platelets that are needed for normal blood clotting,” the agency wrote.
Although J&J has said conditions are rare, it will update product information and continue to work closely with the EMA and other government agencies, according to Reuters.
“We strongly support awareness of the signs and symptoms of rare events to ensure that they can be quickly identified and treated effectively,” the company said in a July statement.
AstraZeneca and Johnson & Johnson vaccines have been linked to rare incidents of blood clotting in the past.
[ad_2]
Source link